Oteseconazole Patent Expiration
Oteseconazole is Used for reducing the incidence of recurrent vulvovaginal candidiasis in females with a history of RVVC who are not of reproductive potential. It was first introduced by Mycovia Pharmaceuticals Inc
Oteseconazole Patents
Given below is the list of patents protecting Oteseconazole, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vivjoa | US10414751 | Antifungal compounds and processes for making | Mar 17, 2036 | Mycovia Pharms |
| Vivjoa | US9840492 | Antifungal compounds and processes for making | Mar 17, 2036 | Mycovia Pharms |
| Vivjoa | US11247981 | Metalloenzyme inhibitor compounds | May 09, 2033 | Mycovia Pharms |
| Vivjoa | US8236962 | Metalloenzyme inhibitor compounds | Apr 22, 2031 | Mycovia Pharms |
| Vivjoa | US8754227 | Metalloenzyme inhibitor compounds | Apr 22, 2031 | Mycovia Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Oteseconazole's patents.
Latest Legal Activities on Oteseconazole's Patents
Given below is the list recent legal activities going on the following patents of Oteseconazole.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eCofC Notification | 05 Mar, 2024 | US11247981 |
| Mail Patent eCofC Notification | 05 Mar, 2024 | US11247981 |
| Email Notification Critical | 05 Mar, 2024 | US11247981 |
| Recordation of Patent eCertificate of Correction | 05 Mar, 2024 | US11247981 |
| Post Issue Communication - Certificate of Correction | 15 Feb, 2024 | US11247981 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 07 Feb, 2024 | US8236962 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Mar, 2023 | US10414751 |
| Initial letter Re: PTE Application to regulating agency | 08 Jul, 2022 | US8236962 |
| Post Issue Communication - Certificate of Correction | 12 May, 2022 | US11247981 |
| Recordation of Patent Grant Mailed Critical | 15 Feb, 2022 | US11247981 |
Oteseconazole's Family Patents
